Respiratory News and Research

RSS

Study finds pulmonary rehab empowers children with respiratory issues

New research presented at the 2026 ATS International Conference shows that pulmonary rehabilitation (PR) significantly improves functioning and quality of life in children with chronic respiratory conditions, regardless of whether lung function itself improves.

18 May 2026

Scientists call for innovative strategies to combat tuberculosis superspreaders

Superspreading became a familiar concept to many during the COVID-19 pandemic. Prior studies examining infectious disease epidemics, including those on COVID-19, have found that some individuals are much more likely to transmit infections to other people. Superspreading, when one person with an infection passes it to an unusually large number of other people, is a key feature of tuberculosis (TB) epidemiology.

15 May 2026

ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

ExiVex Biopharma (formerly EmerRx Biopharma), a clinical-stage pharmaceutical company developing a proprietary dual-chamber intranasal drug delivery platform, today announced in-human pharmacokinetic (PK) data for its lead candidate EMRX-101, an intranasal naloxone product targeting opioid-induced respiratory depression.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 15 May 2026

How Andes virus super-spreaders reveal the risk behind the MV Hondius hantavirus cluster

A 2020 NEJM study of the 2018 to 2019 Epuyén outbreak showed that Andes virus spread from one zoonotic introduction into four generations of human infection, causing 34 cases and 11 deaths. The findings are newly relevant after WHO reported an ANDV cluster linked to the MV Hondius cruise ship, where close indoor exposure may have enabled onboard human-to-human transmission.

14 May 2026

Experts urge WHO to strengthen airborne virus precautionary measures

With three people dead and 11 cases from the recent hantavirus outbreak on a cruise ship, UMD's internationally renowned expert on airborne viruses, Dr. Don Milton, joins public health colleagues in an opinion piece in the British Medical Journal (BMJ) calling on the World Health Organization (WHO) to shift its default response to emerging respiratory viruses.

13 May 2026

Study reveals hidden airborne infection pathways in multi-family buildings

Airborne diseases like measles, influenza and COVID-19 can easily spread between units in multi-family buildings via a type of bathroom ventilation system commonly used around the world, new research suggests.

13 May 2026

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that its Phase 2 trial for ETD001, the Company's lead candidate for treatment of cystic fibrosis (CF), achieved its primary efficacy outcome.

From Enterprise Therapeutics Ltd 12 May 2026

A century of safety: Aluminium vaccine adjuvants do not raise serious long-term health risks

A BMJ systematic review of 59 human studies found no evidence supporting causal links between aluminum-adjuvanted vaccines and serious or long-term outcomes such as autism spectrum disorder, asthma, autoimmune conditions, or other chronic illnesses. The most consistent adverse events were uncommon, local, self-limited persistent nodules or granulomas, likely reflecting delayed-type hypersensitivity.

11 May 2026

Shaping the future of asthma management with the NObreath® at ATS 2026

World leaders in breath analysis Bedfont® Scientific Ltd. are pleased to be attending this years American Thoracic Society (ATS) International Conference, to exhibit the innovative NObreath® Fractional exhaled Nitric Oxide (FeNO) device at booth 1236 alongside its US distributor coVita™.

From Bedfont® Scientific Ltd 11 May 2026

Qureight establishes Scientific Advisory Board focused on pulmonary hypertension

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has established a Scientific Advisory Board (SAB) focused on pulmonary hypertension (PH).

From Qureight 11 May 2026

Hovione and IDC Intranasal Drug Delivery Platform available for commercial partnerships

Hovione, a global integrated specialist CDMO, and Industrial Design Consultancy Ltd (IDC), an international product development company, today announced that their Intranasal Drug Delivery Platform has reached a new milestone, with its lead single-use nasal dry powder device now available for commercial partnerships.

From Hovione 11 May 2026

Breathing polluted air before surgery may worsen recovery outcomes

Findings indicate that elevated fine PM exposure before surgery correlates with higher postoperative complication rates, urging further research in this area.

11 May 2026

Andes hantavirus outbreak highlights global spillover and transmission risks

A Virginia Tech disease ecologist said the outbreak of Andes hantavirus aboard the international MV Hondius cruise ship underscores how little scientists still know about the viruses circulating silently in wild rodent populations before they spill into humans.

11 May 2026

Copper-based nanoplatform shows promise against metastatic tumor growth

What happens if cancer cells lose both their mitochondrial energy supply and their glycolytic backup system? This question is central to a new study published in Research by researchers from Northwestern Polytechnical University and collaborating institutions.

10 May 2026

Cardiometabolic diseases remain leading cause of excess American mortality

Between 1999 and 2022, the US had substantially higher death rates than other wealthy nations, largely due to cardiovascular disease, metabolic diseases (including diabetes), Alzheimer's disease and related dementias, and drug and alcohol complications.

8 May 2026